Will insurance cover my treatment? Currently the treatments are not covered by insurance and will have to be paid for privately. We are working with MAPS to find ways to reduce the impact of cost and utilize health insurance benefits to cover portions of the treatment.
How much does it cost? Currently the cost of the entire treatment protocol is 40k +. This includes all medical and psychological assessments, enrollment costs, 3 preparatory sessions with two therapists, an 8 hour day experimental session with MDMA and both therapists, and 3 integration sessions. After a month, we repeat this process two times.
We will be working hard to get that cost down and doing fundraising. If you would like to donate to help those without financial means to pay for such an important treatment, please contact us. All donations will be tax deductible and go to reducing treatment costs for those without financial means. Our strong commitment is to make this treatment available to everyone: all races, genders, and economic situations.
Currently there are no treatments for PTSD that offer this kind of relief. In MAPS’ completed Phase 2 trials with 107 participants, 61% no longer qualified for PTSD after three sessions of MDMA-assisted psychotherapy two months following treatment. At the 12-month follow-up, 68% no longer had PTSD. All participants had chronic, treatment-resistant PTSD, and had suffered from PTSD for an average of 17.8 years.
If you have further questions, please reach out to us by email or check out the newsletter and website for the latest updates.
Want to learn more? Here is a list of 10 articles on psychedelic research:
The Luminous Healing Center offers a innovative suite of trauma treatments designed to work in concert to promote rapid and lasting healing from psychological trauma.
We are incredibly excited to announce we will soon be offering MDMA-assisted psychotherapy for patients diagnosed with posttraumatic stress disorder (PTSD).
We are excited to be one of the few clinics in the United States with the ability to offer this treatment through an Expanded Access Program under the guidance of the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA) and in collaboration with Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation (MAPS PBC).